What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GIP / GLP-1 / glucagon tri-agonist
Vialdyne primary owner
This is the primary page for Retatrutide buyers who need to evaluate investigational-active sourcing under a pharmacy or regulated-procurement workflow. It focuses on documentation depth, add-on testing, repeat-order route control, and whether the buyer's destination market can accept the active.
Overview
Retatrutide (Eli Lilly's LY3437943) is an investigational 39-residue tri-agonist that engages GIP, GLP-1, and glucagon receptors in a single molecule. Adding the glucagon arm is what separates this asset from the GIP/GLP-1 dual agonists (Tirzepatide) and the GLP-1/glucagon dual agonists (Mazdutide, Survodutide); the glucagon component contributes hepatic energy expenditure on top of the incretin-driven glycaemic and satiety effects, and is the mechanistic reason for the unusually large weight-reduction deltas reported across the Phase 2 program. Vialdyne releases lyophilised Retatrutide acetate against a ≥99.0% main-peak HPLC specification, with a batch packet that includes RP-HPLC peak integration, ESI-MS identity, Karl Fischer water, and counter-ion quantitation. For 503A and 503B compounding traffic and any downstream parenteral use, LAL endotoxin (USP <85>) and bioburden (USP <61>/<62>) are documented as add-on tests on the same lot, no re-sampling. Eight nominal strengths from 5 to 60 mg map onto both bench-scale aliquots and weekly dispensing inventories. Because aggregate world production volume for Retatrutide is still a fraction of what Semaglutide or Tirzepatide command, per-mg pricing is steeper at small quantities but normalises once a repeat order is locked against a defined synthesis route, ask for the 100 g and 1 kg tier sheet at the qualification stage.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for Retatrutide, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →Retatrutide
VD260428-RT170 · 99.33%
VerifiedRequest full COA →Retatrutide
VD260428-RT163 · 99.48%
VerifiedRequest full COA →Retatrutide
VD260428-RT171 · 99.67%
VerifiedRequest full COA →Retatrutide
VD260428-RT164 · 99.23%
VerifiedRequest full COA →Retatrutide
VD260428-RT165 · 99.36%
VerifiedRequest full COA →Retatrutide
VD260428-RT166 · 99.41%
VerifiedRequest full COA →Retatrutide
VD260428-RT167 · 99.33%
VerifiedRequest full COA →Retatrutide
VD260428-RT168 · 99.55%
VerifiedRequest full COA →Retatrutide
VD260428-RT162 · 99.64%
VerifiedRequest full COA →Retatrutide
VD260428-RT169 · 99.53%
Regulatory note
Retatrutide remains investigational, still moving through clinical development, and has not been approved as a finished drug anywhere. We offer it as a pharmaceutical-grade active for research purposes and, in jurisdictions that permit it, for compounding-pharmacy use governed by the receiving pharmacy's quality system. Confirming that compounding is permitted under the destination market's prevailing regulatory posture rests with the buyer.
Selected literature
Frequently asked questions
The headline distinction is the glucagon receptor. Tirzepatide is a dual GIP/GLP-1 co-agonist; Retatrutide adds GCGR engagement, producing tri-mechanism activity. The glucagon arm contributes hepatic-energy-expenditure modulation that the dual class lacks, which in Phase 2 readouts has translated into larger weight-reduction magnitudes than any prior peptide in the metabolic space, including Tirzepatide at matched exposures. Both share a 39-residue scaffold and use C20 fatty-diacid lipidation for albumin-mediated half-life extension, but the receptor-binding determinants and the linker geometry diverge.
Investigational status governs everything. In any jurisdiction, the receiving pharmacy needs to confirm that an unapproved active can be compounded under their local rules, and that the patient-specific or batch-level documentation chain is intact. Three buyer profiles dominate current Retatrutide demand: translational and pre-clinical labs studying tri-agonist receptor pharmacology, 503A compounding pharmacies operating in permissive frameworks under physician prescription, and regulatory-track sponsors assembling IND or comparable submission packages. For the third group we can release the raw chromatograms and mass-spec data files alongside the COA so they drop directly into a CMC dossier.
Three drivers stack. First, world aggregate production volume is still small relative to the GLP-1 mono-agonists, so unit cost has not yet amortised. Second, the synthesis is more demanding, the longer SPPS run requires tighter purification cycles to clear deletion sequences that elute close to the target peak. Third, first-quote economics build in single-run synthesis cost rather than amortised repeat-run cost. Pricing improves materially at the 100 g and 1 kg break points and tightens further once a recurring schedule is locked against a defined route, so it is worth pricing both spot and 12-month commit at the qualification stage.
Related peptides
